Month: February 2022

TORONTO and MINNEAPOLIS, Feb. 24, 2022 (GLOBE NEWSWIRE) — Ceridian (NYSE: CDAY; TSX: CDAY), a global leader in human capital management (HCM) technology, today announced the appointments of Chris Armstrong to Executive Vice President and Chief Operating Officer, and Steve Holdridge to Executive Vice President and Chief Customer Officer. Armstrong and Holdridge will help accelerate the company’s growth and continue to increase the value that customers gain from the Dayforce platform. As Chief Operating Officer, Armstrong will lead global operations, focused on driving scale, efficiency, and growth as the company continues to expand around the world. Since joining Ceridian in 2004, Armstrong has held several senior leadership roles, most recently overseeing the global customer office and the customer experience. In his expanded role...

Not for distribution to U.S. news wire services or dissemination in the United States. TORONTO, Feb. 24, 2022 (GLOBE NEWSWIRE) — Wallbridge Mining Company Limited (TSX:WM, OTCQX:WLBMF), (“Wallbridge” or the “Company”) today announced that further to its press release earlier today, that it has completed its previously-announced non-brokered private placement of 24,611,351 National flow-through common shares (the “National FT Shares”) and 12,357,000 Quebec flow-through common shares (the “Quebec FT Shares”) for aggregate gross proceeds of C$14,172,570 (the “Private Placement”). The National FT Shares were issued at a price of C$0.37 and the Quebec FT Shares at a price of C$0.41. All securities issued pursuant to the Private Placement will have a four month and one day statutory hold period. The gross proceeds from the Private Placement...

 Key 2021 and post period events:Appointment of Dr. Paul Stoffels1 as new CEO, effective 1 April 2022, following planned retirement of CEO and co-founder Onno van de Stolpe Jyseleca sales booked by Galapagos in Europe were €14.8 million out of a total in-market performance of €25.7 million Jyseleca (filgotinib) approved for ulcerative colitis (UC) in Europe and Great Britain, reimbursement for rheumatoid arthritis (RA) secured in 14 countries Patient enrollment completed in the DIVERSITY Phase 3 program with filgotinib in Crohn’s Disease (CD) Discontinuation of development of ziritaxestat, GLPG1690, in Phase 3 program in idiopathic pulmonary fibrosis (IPF) First patient results with salt inducible kinase (SIK) 2/3 inhibitor GLPG3970 support further work on this novel pharmacology Activity observed with selective tyrosine kinase (TYK)...

Phase 2a study in Mitochondrial Encephalomyopathy, Lactic Acidosis, and Stroke-like episodes (MELAS) enrollment closed; topline data expected in Q2 2022      Phase 1b study in Cognitive Impairment Associated with Schizophrenia (CIAS) enrollment ongoing; topline data expected in H2 2022      Phase 2a study in Alzheimer’s Disease with vascular pathology (ADv) enrollment ongoing CAMBRIDGE, Mass., Feb. 24, 2022 (GLOBE NEWSWIRE) — Cyclerion Therapeutics, Inc. (Nasdaq: CYCN), a clinical-stage biopharmaceutical company on a mission to develop treatments that restore cognitive function, announced today clinical development updates for CY6463, its lead program, and additional corporate progress. “We are developing CY6463 as a potentially transformative medicine for cognitive impairment associated with certain CNS diseases that are lacking...

– BDSI Acquisition Expected to Close Late Q1 2022 – – 2022 Revenue Guidance of $315-$330 Million, Growth Driven by Xtampza ER – – Full-Year Net Income of $71.5 Million and Full-Year Adjusted EBITDA of $118.3 million – – Cash Balance of $186.4 Million – – Conference Call Scheduled for Today at 4:30 p.m. ET – STOUGHTON, Mass., Feb. 24, 2022 (GLOBE NEWSWIRE) — Collegium Pharmaceutical, Inc. (Nasdaq: COLL) today reported its financial results for the fourth quarter and full-year 2021 and provided a corporate update. “We strengthened the fundamentals of our pain portfolio in the face of challenging market dynamics throughout 2021, achieved key operational objectives, and completed a restructuring that positions Collegium to embark upon a period of growth and value creation,” said Joe Ciaffoni, President and Chief Executive Officer of...

  Q4-2021   Key ResultsRevenue (millions) $128.7   • Revenue increased 8% compared to Q4 2020• Revenue increased 14% compared to full year 2020• $12.8 million in operating cash flow for Q4 2021• $63.9 million in operating cash flow for the year 2021GAAP EPS $0.05  Non-GAAP EPS $0.47       PLEASANTON, Calif., Feb. 24, 2022 (GLOBE NEWSWIRE) — Natus Medical Incorporated (NASDAQ:NTUS) (the “Company” or “Natus”), a leading provider of medical device solutions to screen, diagnose, and treat disorders affecting the brain, neural pathways, and eight sensory nervous systems, today announced financial results for the three months and full year ended December 31, 2021. For the fourth quarter ended December 31, 2021, the Company reported revenue of $128.7 million, an increase of 8.4% compared to $118.7 million reported for...

NEW YORK, Feb. 24, 2022 (GLOBE NEWSWIRE) — Silvercrest Asset Management Group Inc. (NASDAQ: SAMG) announced today it will host a teleconference at 8:30 am Eastern Time on March 4, 2022, to discuss the company’s financial results for the fourth quarter and year ended December 31, 2021. A news release containing the results will be issued before the open of the U.S. equity markets and will be available on http://ir.silvercrestgroup.com/. Chairman, Chief Executive Officer and President Richard R. Hough III and Chief Financial Officer Scott A. Gerard will review the quarterly results during the call. Immediately after the prepared remarks, there will be a question and answer session for analysts and institutional investors. Analysts, institutional investors and the general public may listen to the call by dialing 1-844-836-8743 or...

Fourth quarter revenue Up 24% to $20.3 million, gross profit margin of 61% Introduction of key performance indicators (KPIs) representing “land and expand” strategy with key customer accounts Cash flow positive from operations of $0.7 million in 2021ROCHESTER, Mich., Feb. 24, 2022 (GLOBE NEWSWIRE) — OptimizeRx Corp. (the “Company”) (Nasdaq: OPRX), a leading provider of point-of-care technology solutions helping patients start and stay on therapy, reported results for the fourth quarter and full year ended December 31, 2021.Key Performance Indicators (KPIs)*    FY21  FY20   Average revenue per top 20 pharmaceutical manufacturers    $2.5M  $1.9M   Percent top 20 pharmaceutical manufacturers that are clients  95 % 85 %  Top 20 pharmaceutical percent of total net revenues 77 % 76 %  Net revenue retention  127%    160 %  Revenue...

Gevo to Host Conference Call Today at 4:30 p.m. EDT/2:30 p.m. MDT ENGLEWOOD, Colo., Feb. 24, 2022 (GLOBE NEWSWIRE) — Gevo, Inc. (NASDAQ: GEVO) today announced financial results for the fourth quarter of 2021 and summarized recent corporate highlights. Recent Corporate HighlightsOn December 7, 2021, Kolmar Americas Inc and Gevo entered into a financeable fuel supply agreement for 45 million gallons per year of renewable, energy-dense liquid hydrocarbons. On November 16, 2021, Gevo signed a memorandum of understanding (MoU) with Sweetwater Energy, Inc., regarding the use of sustainably sourced agricultural residues and woody biomass as a feedstock for producing cellulosic alcohols and energy-dense renewable liquid hydrocarbons. On October 25, 2021, ADM, a global leader in nutrition and agricultural origination and processing, and...

Four top-line data readouts expected in 2022 from ongoing oral AMT-101 Phase 2 trials, as followsFILLMORE monotherapy trial for patients with chronic pouchitis followed by MARKET combination trial with anti-TNFα in ulcerative colitis (UC) in H1 2022 LOMBARD monotherapy trial in UC and CASTRO combination trial with anti-TNFα in rheumatoid arthritis (RA) in H2 2022Phase 1 ongoing for second product candidate, oral AMT-126, with program update in H1 2022 SOUTH SAN FRANCISCO, Calif., Feb. 24, 2022 (GLOBE NEWSWIRE) — Applied Molecular Transport Inc. (Nasdaq: AMTI) (AMT), a clinical-stage biopharmaceutical company, today provided a corporate update and reported financial results for the fourth quarter and full year ended December 31, 2021. “We are looking forward to a catalyst-rich year in 2022 for AMT,” said Tahir Mahmood, Ph.D.,...